Is Johnson & Johnson the Best Dividend Stock in Healthcare?
Johnson & Johnson (NYSE: JNJ) has increased the amount of money it returns to investors in the form of dividends every year for more than 50 years. Its diversification across various healthcare segments offers insulation against industry-specific risks to over-the-counter, pharmaceutical, and medical device demand, and a bulletproof balance sheet provides plenty of financial flexibility that management can use to acquire and develop new products.
Is now the right time to buy this dividend darling? In this clip from The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes is joined by contributor Todd Campbell to highlight the pros and cons of investing in this top-tier dividend stock.
A full transcript follows the video.
Source: Fool.com
Johnson & Johnson Stock
The stock is one of the favorites of our community with 41 Buy predictions and 1 Sell predictions.
With a target price of 196 € there is a positive potential of 34.06% for Johnson & Johnson compared to the current price of 146.2 €.
